Home > Dermatology > AAD 2023 > AAD 2023 Highlights Podcast

AAD 2023 Highlights Podcast

Presented by
Robert van den Heuvel, Medicom
AAD 2023

In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the American Academy of Dermatology (AAD 2023), held in New Orleans, LA, USA, from 17-21 March 2023.
The topics discussed are:

  1. Blockade of the IL-22 receptor: a novel treatment approach in AD
    IL-22 might be a novel target in the therapy of moderate-to-severe atopic dermatitis. In a first phase 2a study, an investigative IL-22 receptor blocker achieved all primary and secondary endpoints and was well tolerated.
  2. Psoriasis: Biologics may impede the incidence of psoriatic arthritis
    Retrospective data revealed a significantly lower incidence of psoriatic arthritis (PsA) in patient with psoriasis when treated with biologics compared with phototherapy. This was demonstrated by a difference of -25.5 cases of PsA per 1,000 person years in the biologics group.
  3. Baricitinib therapy: a new hope for patients with lichen planus
    Baricitinib might be on track of becoming a viable treatment option for lichen planus. Within a first-in-human trial, response to treatment was observed in more than 90% of patients.
  4. Selective investigative TYK2 inhibitor: a new potent oral medication for psoriasis?
    A novel tyrosine kinase 2 (TYK2) inhibitor showed remarkable efficacy in psoriasis with one-third of patients reaching a Psoriasis Area and Severity Index (PASI) 100 in the highest dose. The safety profile was acceptable and in line with experiences from earlier trials with TYK2 inhibitors.
  5. Bimekizumab: the new rising star for HS therapy?
    Within the BE HEARD trial, bimekizumab treatment resulted in meaningful benefits in the treatment of hidradenitis suppurativa. After 48 weeks of treatment, about half of the patients achieved a 50% hidradenitis suppurativa clinical response.
  6. Topical delgocitinib efficacious in chronic hand eczema
    Pan-JAK inhibition with delgocitinib met its primary endpoint in the DELTA 1 trial for the treatment of chronic hand eczema. Significantly more patients presented clear or almost clear skin in the Investigator’s Global Assessment (IGA) at week 16.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers

Posted on